is the fda banning tirzepatide 🚨 Important Update on Compounded 🚨, As of March 19th, has officially banned compounded Tirzepatide formulations. We believe this a huge disservice to patients seeking affordable 🚨 FDA Moves to Permanently

58 Consequently, GLP-1 RAs are currently evidence-based treatments for common conditions that not only differentially affect persons with SMI-SUD but also contribute to the morbidity and mortality of these conditions

A complete list of baseline cohort characteristics is provided in Table 1

Semaglutide works primarily on the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors, creating potential synergy when used together

The 180-day exclusivity is the most profitable event in the generic industry

It can be prescribed to: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight and a weight-related health condition, such as high cholesterol, high blood pressure, type 2 diabetes, or sleep apnea Adults who have heart disease and either obesity or overweight Some people should avoid taking Wegovy